US FDA generics chief moves to new role
This article was originally published in Scrip
Gary Buehler, who has been the head of the US Food and Drug Administration’s Office of Generic Drugs for nearly a decade, is moving to a new role within the agency. In his new position, Mr Buehler will play a key role in negotiations and activities relating to generic drug user fees.
You may also be interested in...
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
Securing accelerated assessment for a drug in any regulatory jurisdiction is a major boost for drug companies, but it does not necessarily translate into an earlier reimbursement decision.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.